By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


New inhaler combines fluticasone and formoterol

A new prescription combination treatment for asthma patients is now available that contains fluticasone and formoterol in a single inhaler.

The medicine is available in three strengths - two low-level types for adults and adolescents aged at least 12 years, and the strongest for adults aged 18 years and over.

The inhaler contains a colour coded dose indicator so that patients can ascertain how much medication is left in the device.

This will be the first time that a single inhaler contains a combination of fluticasone propionate (fluticasone), an inhaled corticosteroid (ICS) and formoterol fumarate (formoterol), a long-acting β2-agonist (LABA).

The fluticasone/formoterol combination inhaler is being marketed under the brand name Flutiform and is manufactured by Napp Pharmaceuticals Limited.

Stephanie Wolfe, a respiratory nurse specialist from Norfolk, said: “Data from a recent survey suggested that despite perception of good control many patients still have symptoms and a small but significant number of people are still visiting A&E.”

Ms Wolfe added: “We know from experience that regular reviews allow us to monitor a patient’s condition, educate them about effective inhaler technique and importantly ensure they receive the best possible treatments that match their individual needs.

“Choice is therefore important and we welcome new combination treatment options that may help to further achieve this.”

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!